Tan, Antoinette R. http://orcid.org/0000-0002-7895-7000
O’Shaughnessy, Joyce http://orcid.org/0000-0002-2955-5523
Cao, Subing
Ahn, Sarah
Yi, John S. http://orcid.org/0000-0001-7777-2437
Funding for this research was provided by:
G1 Therapeutics
Article History
Received: 12 April 2023
Accepted: 11 June 2023
First Online: 7 July 2023
Declarations
:
: Antoinette R. Tan reports institutional clinical trial support and personal fees from G1 Therapeutics, Inc.; outside of the submitted work, institutional clinical trial support from Arvinas, Genentech/Roche, Merck, and Pfizer, and personal fees from AstraZeneca, Genentech/Roche, Jazz Pharmaceuticals, Novartis, Puma, Seagen, and Stemline Therapeutics. Joyce O’Shaughnessy reports institutional clinical trial support and personal fees from G1 Therapeutics, Inc.; outside of the submitted work, personal fees from AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BMS, Celgene, Eisai, Genentech, Immunomedics, Ipsen, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, Prime Oncology, Puma Biotechnology, Roche, Seattle Genetics, and Syndax Pharmaceuticals. Subing Cao and Sarah Ahn (at the time of the study), and John S. Yi are paid employees and shareowners of G1 Therapeutics, Inc.
: The study (NCT02978716) was designed and conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation. The protocol and all study-related materials were approved by the institutional review board or independent ethics committee of each investigational site.
: Written informed consent was obtained from all individual participants included in the study.
: Not applicable.